Envista (NYSE:NVST) Stock Rating Lowered by Wall Street Zen

by · The Cerbat Gem

Wall Street Zen lowered shares of Envista (NYSE:NVST – Free Report) from a strong-buy rating to a buy rating in a research report report published on Saturday morning.

Other equities analysts have also issued research reports about the stock. UBS Group lifted their price target on shares of Envista from $18.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, July 29th. Wells Fargo & Company raised their target price on Envista from $17.00 to $19.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Piper Sandler lifted their target price on Envista from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Friday, August 1st. Evercore ISI increased their price target on Envista from $19.00 to $23.00 and gave the company an “outperform” rating in a research note on Wednesday, July 9th. Finally, Stifel Nicolaus raised their price objective on Envista from $24.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Envista currently has a consensus rating of “Hold” and a consensus target price of $20.92.

Read Our Latest Stock Report on Envista

Envista Stock Performance

Shares of NVST stock opened at $21.15 on Friday. The firm has a market capitalization of $3.51 billion, a price-to-earnings ratio of 66.08, a PEG ratio of 1.13 and a beta of 0.99. The company has a current ratio of 2.44, a quick ratio of 2.08 and a debt-to-equity ratio of 0.46. The business’s 50-day moving average price is $20.33 and its 200-day moving average price is $18.57. Envista has a 12 month low of $14.22 and a 12 month high of $23.00.

Envista (NYSE:NVST – Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.02. Envista had a net margin of 2.11% and a return on equity of 4.84%. The business had revenue of $682.10 million during the quarter, compared to analyst estimates of $638.21 million. During the same quarter last year, the business earned $0.11 EPS. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. Envista has set its FY 2025 guidance at 1.050-1.15 EPS. Equities research analysts forecast that Envista will post 1 EPS for the current year.

Institutional Investors Weigh In On Envista

Several institutional investors and hedge funds have recently made changes to their positions in NVST. UMB Bank n.a. grew its stake in Envista by 214.4% during the first quarter. UMB Bank n.a. now owns 2,094 shares of the company’s stock worth $36,000 after purchasing an additional 1,428 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Envista by 73.1% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after buying an additional 949 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Envista by 378.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock worth $47,000 after buying an additional 1,909 shares during the period. Parallel Advisors LLC increased its stake in shares of Envista by 100.1% in the 2nd quarter. Parallel Advisors LLC now owns 2,792 shares of the company’s stock valued at $55,000 after acquiring an additional 1,397 shares in the last quarter. Finally, Palouse Capital Management Inc. lifted its position in shares of Envista by 14.4% during the 1st quarter. Palouse Capital Management Inc. now owns 9,444 shares of the company’s stock valued at $163,000 after acquiring an additional 1,186 shares during the period.

About Envista

(Get Free Report)

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.

Read More